ArticleFrontiers in oncology2026

Reclassifying contralateral axillary metastasis: survival benefit of aggressive local therapy challenges stage IV designation.

Shanqing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.